Connect with us

BUSINESS

Fiore Cannabis Ltd (OTCMKTS: FIORF) Expands its Core US Markets by Finalizing the Sale of its Final Celista, BC Canadian Asset

Published

on

Thanks to increased investment and legalization, there is so much energy and excitement in the cannabis industry, resulting in expansion and growing retail businesses. Since its founding in 2014, Fiore Cannabis Ltd (OTCMKTS: FIORF) has encountered diverse unmet needs from consumers, promoting a need for an enlarged portfolio of branded products. As a result, the company has invested heavily in developing recreational, medical, and wellness cannabis products. Its current brands include Diamante Labs, The Weekender, Fiore Cannabis, Surfer, and PureCloud 9.

For the last couple of summer months, Fiore Cannabis has been planning and strategizing on its direction. And once of the accomplishments is the completion of the sale of its Celista, BC asset. The company’s CEO, Erik Anderson, says that this is one of the wins for them to clean up their balance sheet. This will also enable the company to refocus on allocating its key markets, including Nevada and California. Meanwhile, preparation of operations is underway in Las Vegas and Desert Hot Springs in California’s Coachella Valley. 

The Acquisition of a California Cannabis Delivery Firm

At the cost of US$1.2 million payable in a stock and cash transaction, Fiore Cannabis Ltd. has acquired a cannabis delivery business, California Patients Club (CPC). The acquisition will play a significant role in the integration of its service offering in California. 

Speaking about this partnership, CPC’s owner John Jacobs says that having developed a top-tier e-commerce business, they have the scale and ability to expand it beyond its current market. And there is no other better opportunity than now, given the significant increase in the California cannabis market. 

Marijuana Business Daily has it that this particular market topped US$4.4 billion in sales in 2020. Besides, the regulations in California are so supportive of the delivery business. Meanwhile, the acquisition’s closure should happen in 90 days as both parties take one step towards realizing its objective. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) And Avicanna Inc. Enter Product Licensing and Royalty Agreement

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has signed an exclusive IP licensing and royalty deal with Avicanna Inc. Avicanna is a biopharmaceutical firm specializing in the development, production, and marketing of plant-derived CBD products. 

Heritage to avail Avicanna products on Q4 

The Licensing Agreement covers the marketing of Avicanna’s advanced CBD-based topical treatments under Heritage’s medical cannabis brands. Avicanna’s patented cannabis topical products, created years of comprehensive research by the company’s scientists, are among the Branded Products. The formulations are supported with pre-clinical research, including two SKUs backed with complete human trials. Heritage’s vast medical sales channels across Canada will introduce the Branded Products in Q4 2021.

Umar Syed, Heritage’s president for the medical division, commented, “We are excited to add Avicanna’s innovative topical products to our portfolio of highly effective medical CBD products. They are a great strategic fit. We are very impressed with Avicanna’s diligent R&D approach for developing highly effective topical products formulated with pharmaceutical technology and which are supported with evidence of efficacy, much like the existing Opticann portfolio that includes oral products that use the patented VESIsorb technology and sublingual CBD filmstrips that use the patented Versafilm technology. The Licensing Agreement offers Heritage speed-to-market with highly effective topicals and we see this as the beginning of a highly successful commercial partnership.”

Avicanna to receive royalty payment on sales 

Avicanna has exclusively licensed, subject to certain conditions and exceptions, the use of certain proprietary product formulations to Heritage to be sold and marketed under Heritage’s medical Opticann branded products throughout Canada under the terms of the Licensing Agreement. The agreement has an initial three-year period. In addition, heritage must reach specified annual sales targets for each Branded Product licensed under the Licensing Agreement, and it will pay Avicanna a royalty for products sold.

Aras Azadian, Avicanna CEO, said, “We look forward to collaborating with the Heritage team to extend our proprietary and evidence-based topical formulations to more Canadian patients and expand into more medical channels nationwide.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Revive Therapeutics Ltd (OTCMKTS: RVVTF) Updates About its Programs, and Cartel Blue Ord Shs (OTCMKTS: CRTL) Announces Launch of Premium Hemp Cigar Lounges and Product Showrooms

Published

on

Revive Therapeutics Ltd (OTCMKTS: RVVTF) announced an update regarding its psilocybin focussed psychedelics development and clinical programs. The specialty life sciences company works on research and development therapeutics for medical needs and rare disorders. 

The company aims to unlock the potential therapeutic value of psilocybin

Michael Frank, CEO of Revive Therapeutics Ltd stated that the company is working on clinical studies to open the actual potential therapeutic value of psilocybin in its multiple uses, besides working on ways to treat mental health, substance abuse, and neurological disorders. 

The CEO went on record and stated that the company is headed towards its next growth stage, focusing on entering into a partnership with U.S. academic institutions and other organizations. The company is also developing intellectual property and venturing into FDA clinical studies with psilocybin, stated the CEO. 

Development of Psilocybin oral thin-film strip underway

As part of a feasibility agreement with LTS Lohmann Therapie-Systeme AG, the company has started its product development program. Under the initiative, the development and manufacturing of a proprietary psilocybin oral thin-film strip will be done. The product can be used to treat substance abuse, mental illness, and neurological disorders. Clinical studies will be conducted in 2022. 

Cartel Blue Ord Shs (OTCMKTS: CRTL) confirms launch of premium hemp cigar lounges and product showrooms

Cartel Blue Ord Shs (OTCMKTS: CRTL) announced the launch of its first premium hemp cigar lounges and its product showrooms. According to a statement issued by the company, the three Cartel Premium Cigar Lounges will be opened in Nashville, Cathedral City, and Honolulu. As a result, the Premium Hemp smoker can take advantage of Cartel products in a secure and comfortable environment at the new locations. 

It is learned that Cartel Blue Ord Shs will be granted the liquescence to sell products with Hawaii Grown and Product of the Kingdom of Hawaii trademarks in locations where Cartel Blue products are marketed and sold. Additionally, a source from the company shared that Alan Ada of Pointe West Pacific Development is responsible for the construction, expansion, and management of all the facilities in line with the Cartels business model.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Pharmacyte Biotech Inc (NASDAQ: PMCB) IOP Closes and the Company’s Common Stock Begins to Trade on NASDAQ

Published

on

Pharmacyte Biotech Inc (NASDAQ: PMCB) announced the closure of underwritten public offering valued at $15 million. The company’s stock are currently trading on NASDAQ.

H.C. Wainwright appointed as sole book-running manager

The company chose to have H.C. Wainwright as its sole book-running manager for the offering. A written prospectus, prospectus supplement about the offering and registration statement on Form S-3 (File No. 333-255044) that was previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (SEC) on April 14, 2021, were filed as part of the offering. 

A source from the company shared that the final prospectus supplement and accompanying prospectus on the offer is filed with the SEC, besides being available on SEC’s official website. In addition, electronic copies of the prospectus could be obtained, the source added. 

Information about the IPO

More than 3.5 million shares of the company’s common stock and warrants to purchase up to an aggregate of the same number of common stock were part of the IPO. Besides this, the company granted the underwriter an option of 30-days to purchase additional shares of its common stock, besides being given a choice to buy accompanying company warrants. 

After deducting underwriting discounts, commissions, and other offering expenses, Pharmacyte Biotech Inc earned net proceeds of around $13.6 million from the IPO during closure. 

Pharmacyte Biotech Inc stock begins to trade 

Pharmacyte Biotech Inc stock begins to trade on the Nasdaq Capital Market. The IPO offering of the company closed, and under the symbol PMCB, the stock of the company commenced its trading journey. The company in the biotechnology sector is developing cellular therapies for cancer and diabetes. The treatments are made based on a cellulose-based live-cell technology christened Cell-in-a-Box®. The team of experts at the company produces various therapies to treat cancer and diabetes. 

Therapies developed by the company convert inactive chemotherapy drugs into cancer-killing form

Therapies developed by Pharmacyte Biotech Inc for cancer involve genetically engineered human cells that are capable of converting an inactive chemotherapy drug into its active or cancer-killing form.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories